Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Speculation regarding a potential fundraise

10 Feb 2022 13:33

RNS Number : 3385B
Omega Diagnostics Group PLC
10 February 2022
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Speculation regarding a potential fundraise

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes today's online speculation and confirms that it has conditional investor support for an equity fundraising at 5p per share and that it is considering undertaking a share placing to raise approximately £5m with an accompanying open offer to raise up to a further £2m.

 

Any such fundraising would however be conditional upon certain other corporate actions currently being explored by the Group and, accordingly, there is no certainty at this time that any such fundraise will proceed.

 

A further announcement will be made in due course as necessary.

 

 

Contacts: 

 

Omega Diagnostics Group PLC

www.omegadx.com

Jag Grewal, Chief Executive Officer

via Walbrook PR

Chris Lea, Chief Financial Officer

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

Alice Lane/ Charlotte Sutcliffe (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

 

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRSFEFDSEESEDE
Date   Source Headline
16th Apr 200710:36 amRNSEuropean patent grant
4th Apr 20077:02 amRNSAppointment of Distributor
30th Mar 20076:20 pmRNSInterim Results
15th Dec 20062:28 pmRNSTotal Voting Rights
6th Nov 20067:00 amRNSEuropean patent grant
4th Oct 20069:37 amRNSIssue of Equity
27th Sep 20067:00 amRNSInterim Results
20th Sep 20065:15 pmRNSChange of Name
19th Sep 20067:02 amRNSCommencement of dealings
18th Sep 20062:58 pmRNSResult of EGM
5th Sep 200612:13 pmRNSSch1-Quintessentially English
24th Aug 200611:51 amRNSRestoration of Trading-Amend
24th Aug 200610:30 amRNSRestoration of Trading
24th Aug 200610:30 amRNSRestoration-Quintessentially
24th Aug 20067:00 amRNSAcquisition and Placing
8th May 200612:34 pmRNSResult of AGM
3rd Apr 20067:02 amRNSTemporary Suspension
3rd Apr 20067:01 amRNSSuspension - Quintessentially
23rd Mar 20064:13 pmRNSFinal Results
28th Sep 20057:02 amRNSInterim Results
12th Aug 200512:17 pmRNSResult of AGM
28th Jun 200511:40 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.